Quantum Biopharma Ltd QNTM

$2.94 -0.17 (-5.47%)

Valuation

Market cap
25,152,000
Revenue TTM
$0
Net income TTM
$-26,180,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
129,600
Avg volume
240,114
Day's range
$2.94 – $3.11
Shares out
8,087,000
Stochastic %K
0%
Beta
0.39
Analysts
Strong Sell
Price target
$21.75

Price

Company profile

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of de...

Show more

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is based in Toronto, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
833-304-0323
Website
https://www.quantumbiopharma.com
Address
1 Adelaide Street East, Suite 801, Toronto, Canada

Latest news

Stocktwits

DipBuyPro Oct 9, 8:56 PM
If you like to find the runners early - Join the group of bulls below One of the best FREE small cap communities i know of 🔥 🫡💯 $QNTM $SEGG Loaded up
0 replies
James23db Oct 9, 6:13 PM
$QNTM relentless
0 replies
FickleFin Oct 9, 1:59 PM
$QNTM UNBUZZD shit #'s. Look at sales over expenses 😵‍💫🤡 dead stock. (And they want to IPO. @IncognitoBull called it years ago...$GNS
0 replies
James23db Oct 9, 1:53 PM
$QNTM picked up 40 more. ATL’s incoming?
0 replies
Rambler1111 Oct 8, 5:47 PM
$QNTM $QNTM With Grant and Eisenhofer representing Quantum as the lead prosecutor it means the world . The are also the lead Prosecutors for GNS and are the best for bringing down big companies in these spoofing cases. QNTM is gonna be just fine . Be patient and tune out all the bears that will want you to sell out. HOLD ON BABY, because the lawyers representing have the best credentials and proof or they wouldn’t have taken it on.
0 replies
ZacksResearch Oct 8, 4:42 PM
$QNTM just got a major legal development — but what does it mean for shareholders? The U.S. District Court for the Southern District of New York agreed to consolidate Quantum BioPharma’s direct action with a class action alleging market manipulation through “spoofing” techniques. The court also appointed Grant & Eisenhofer P.A. as lead counsel in the class action. See what Wall Street expects next 👉 https://www.zacks.com/stock/research/QNTM/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-39837&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_39837
0 replies
James23db Oct 7, 4:35 PM
$QNTM nobody wants to buy and lose all of their money with me?
0 replies
NetworkNewsWire Oct 7, 2:21 PM
$QNTM Enlists Thermo Fisher’s Clinical Research Business to Launch Phase 2 Lucid-MS Trial https://ibn.fm/e63yk
0 replies